Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
about
CYP17 inhibitors in prostate cancer: latest evidence and clinical potentialAbiraterone in the management of castration-resistant prostate cancer prior to chemotherapyThe DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistanceNew Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.Role of OATP transporters in steroid uptake by prostate cancer cells in vivo.Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.Characterization of Prostate Cancer in a Functional Eunuch.Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.
P2860
Q26740070-1B7D72ED-911A-4BA4-AF88-0390BED0F7AEQ26786543-60A32C94-869A-458D-AB14-9BF0C68328DEQ35553876-67B7CE06-DC6B-4496-928A-37F3B5ED18B7Q35793871-F339D94C-A1A9-4B42-AEF1-8CCA0BA2D10EQ36470627-D7DF426E-B103-4BEE-8401-38EECA5541CEQ38994718-BF6370EF-164B-4FD9-A8B3-FF90E556A11DQ39373966-DA0274AB-95F7-494E-AA44-F20A7F56E496Q45988129-627D8DEB-6D42-4061-AE3C-E5D2F0683086Q47132254-B7E85F23-D032-4187-8B01-8CC40180E7B4Q51244133-B7D3EB1F-5BC5-48D2-9B9D-26B54AB7378FQ55074422-EB1D7722-3D45-4E56-9D15-7851B3AD92B5Q55441916-18C875AE-FEF4-4F49-BBBC-0A9D5C81DD0D
P2860
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Sequential use of the androgen ...... alue of circulating androgens.
@ast
Sequential use of the androgen ...... alue of circulating androgens.
@en
Sequential use of the androgen ...... alue of circulating androgens.
@nl
type
label
Sequential use of the androgen ...... alue of circulating androgens.
@ast
Sequential use of the androgen ...... alue of circulating androgens.
@en
Sequential use of the androgen ...... alue of circulating androgens.
@nl
prefLabel
Sequential use of the androgen ...... alue of circulating androgens.
@ast
Sequential use of the androgen ...... alue of circulating androgens.
@en
Sequential use of the androgen ...... alue of circulating androgens.
@nl
P2093
P2860
P1476
Sequential use of the androgen ...... alue of circulating androgens.
@en
P2093
Allison Morse
Andrea L Harzstark
Arturo Molina
Charles J Ryan
Eric J Small
Gerald Fetterly
James L Mohler
John H Wilton
Lawrence Fong
P2860
P304
P356
10.1158/1078-0432.CCR-14-1595
P407
P577
2014-10-21T00:00:00Z